Agnès Guerci

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Hematological Malignancy, Oncology, Chronic Myeloid Leukaemia +8

Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia

François Guilhot, Claude Chastang, Mauricette Michallet et al. · New England Journal of Medicine · 1997 · 553 citations · Full text

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

Lionel Adès, Agnès Guerci, Emmanuel Raffoux et al. · Blood · 2009 · 250 citations

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

Christian Rosé, Sabine Bréchignac, D. Vassilief et al. · Leukemia Research · 2010 · 195 citations

Chelation Therapy, Medicine, Iron Metabolism +6

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

Lionel Adès, Sylvie Chevret, Emmanuel Raffoux et al. · Journal of Clinical Oncology · 2006 · 166 citations · Full text